WO2006078277A3 - Dalbavancin compositions for treatment of bacterial infections - Google Patents

Dalbavancin compositions for treatment of bacterial infections Download PDF

Info

Publication number
WO2006078277A3
WO2006078277A3 PCT/US2005/014355 US2005014355W WO2006078277A3 WO 2006078277 A3 WO2006078277 A3 WO 2006078277A3 US 2005014355 W US2005014355 W US 2005014355W WO 2006078277 A3 WO2006078277 A3 WO 2006078277A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
dalbavancin
bacterial infection
bacterial infections
dosing regimens
Prior art date
Application number
PCT/US2005/014355
Other languages
French (fr)
Other versions
WO2006078277A2 (en
Inventor
Martin Stogniew
Luigi Colombo
Romeo Ciabatti
Original Assignee
Vicuron Pharm Inc
Martin Stogniew
Luigi Colombo
Romeo Ciabatti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA06012301A priority Critical patent/MXPA06012301A/en
Priority to KR1020087011850A priority patent/KR100930982B1/en
Priority to JP2007510906A priority patent/JP5207734B2/en
Priority to EP05856652A priority patent/EP1748786A4/en
Application filed by Vicuron Pharm Inc, Martin Stogniew, Luigi Colombo, Romeo Ciabatti filed Critical Vicuron Pharm Inc
Priority to AU2005325261A priority patent/AU2005325261B2/en
Priority to BRPI0510269A priority patent/BRPI0510269B8/en
Priority to NZ550053A priority patent/NZ550053A/en
Priority to NO20064287A priority patent/NO345529B1/en
Priority to CN2005800185632A priority patent/CN1964736B/en
Priority to CA2564112A priority patent/CA2564112C/en
Publication of WO2006078277A2 publication Critical patent/WO2006078277A2/en
Priority to IL178207A priority patent/IL178207A/en
Publication of WO2006078277A3 publication Critical patent/WO2006078277A3/en
Priority to HK07108162.8A priority patent/HK1103639A1/en
Priority to AU2011200423A priority patent/AU2011200423B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A0, A1, B1, B2, CO, C1, isoB0, and MAG, in the presence of low level solvent. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimens include multiple dose administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection. Dosing regimens for renal patients are also included.
PCT/US2005/014355 2002-11-18 2005-04-26 Dalbavancin compositions for treatment of bacterial infections WO2006078277A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
BRPI0510269A BRPI0510269B8 (en) 2004-04-27 2005-04-26 dalbavancin compositions for the treatment of bacterial infections
JP2007510906A JP5207734B2 (en) 2004-04-27 2005-04-26 Dalbavancin composition for treating bacterial infections
EP05856652A EP1748786A4 (en) 2004-04-27 2005-04-26 Dalbavancin compositions for treatment of bacterial infections
NO20064287A NO345529B1 (en) 2004-04-27 2005-04-26 Dalbavancin materials for the treatment of bacterial infections
AU2005325261A AU2005325261B2 (en) 2002-11-18 2005-04-26 Dalbavancin compositions for treatment of bacterial infections
KR1020087011850A KR100930982B1 (en) 2004-04-27 2005-04-26 Dalbavancin compositions for treatment of bacterial infections
NZ550053A NZ550053A (en) 2004-04-27 2005-04-26 Dalbavancin compositions for treatment of bacterial infections
MXPA06012301A MXPA06012301A (en) 2004-04-27 2005-04-26 Dalbavancin compositions for treatment of bacterial infections.
CN2005800185632A CN1964736B (en) 2004-04-27 2005-04-26 Dalbavancin compositions for treatment of bacterial infections
CA2564112A CA2564112C (en) 2004-04-27 2005-04-26 Dalbavancin compositions for treatment of bacterial infections
IL178207A IL178207A (en) 2004-04-27 2006-09-20 Pharmaceutical compositions comprising dalbavancin and/or mannosyl aglycone for the treatment of bacterial infections
HK07108162.8A HK1103639A1 (en) 2004-04-27 2007-07-27 Dalbavancin compositions for treatment of bacterial infections
AU2011200423A AU2011200423B2 (en) 2002-11-18 2011-02-01 Dalbavancin compositions for treatment of bacterial infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/834,395 US7119061B2 (en) 2002-11-18 2004-04-27 Dalbavancin compositions for treatment of bacterial infections
US10/834,395 2004-04-27

Publications (2)

Publication Number Publication Date
WO2006078277A2 WO2006078277A2 (en) 2006-07-27
WO2006078277A3 true WO2006078277A3 (en) 2006-10-19

Family

ID=36692659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014355 WO2006078277A2 (en) 2002-11-18 2005-04-26 Dalbavancin compositions for treatment of bacterial infections

Country Status (17)

Country Link
US (2) US7119061B2 (en)
EP (1) EP1748786A4 (en)
JP (2) JP5207734B2 (en)
KR (2) KR100930982B1 (en)
CN (1) CN1964736B (en)
AU (2) AU2005325261B2 (en)
BR (1) BRPI0510269B8 (en)
CA (1) CA2564112C (en)
HK (1) HK1103639A1 (en)
IL (1) IL178207A (en)
MX (1) MXPA06012301A (en)
NO (1) NO345529B1 (en)
NZ (2) NZ588109A (en)
RU (2) RU2352353C2 (en)
SG (1) SG152274A1 (en)
WO (1) WO2006078277A2 (en)
ZA (2) ZA200607888B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20050090433A1 (en) * 2002-11-18 2005-04-28 Vicuron Pharmaceuticals, Inc Dalbavancin compositions for treatment of bacterial infections
BR112014030279A2 (en) 2012-06-07 2017-09-12 Los Angeles Childrens Hospital Methods for Treatment of Neutropenia Using Retinoid Agonists
CN103087918B (en) * 2013-02-20 2015-04-22 广州市微生物研究所 Aerobic denitrifying fungicide, preparation and applications thereof
WO2015126989A1 (en) 2014-02-18 2015-08-27 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
JP6712991B2 (en) * 2014-07-17 2020-06-24 ザ メディシンズ カンパニー High-purity oritavancin and method for producing the same
US20200171124A1 (en) 2016-04-15 2020-06-04 Lupin Limited Topical compositions for ophthalmic and otic use
BR112018072948A2 (en) * 2016-05-09 2019-02-19 Xellia Pharmaceuticals Aps liquid pharmaceutical composition; and, method for stabilizing a glycopeptide antibiotic in a liquid pharmaceutical solution.
EP3544616A4 (en) * 2016-11-23 2020-12-09 Gufic Biosciences Limited Lyophilized pharmaceutical compositions of dalbavancin
CN109946398B (en) * 2019-03-28 2022-05-24 丽珠集团新北江制药股份有限公司 Method for detecting dalbavancin and impurities thereof
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN111686240B (en) * 2020-06-14 2021-04-09 中国科学院昆明动物研究所 Application of dalbavancin in preparation of medicines for inhibiting combination of SARS-CoV-2 and ACE2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1496386A (en) 1975-03-05 1977-12-30 Lepetit Spa Antibiotics
US4195079A (en) 1979-01-31 1980-03-25 Pfizer Inc. New polycyclic ether antibiotic
CA1183789A (en) 1981-08-04 1985-03-12 Kiyoshi Isono Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient
US4578271A (en) 1982-05-24 1986-03-25 Fujisawa Pharmaceutical Co., Ltd. Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions
FI73697C (en) 1982-06-08 1987-11-09 Lepetit Spa FOERFARANDE FOER FRAMSTAELLNING AV INDIVIDUELLA FAKTORER 1, 2, 3, 4 OCH 5 AV TEIKOMYSIN A2.
FR2548021B1 (en) 1983-06-29 1986-02-28 Dick P R PROLONGED AND CONTINUOUS DERMAL PHARMACEUTICAL COMPOSITIONS BASED ON ESSENTIAL FATTY ACIDS
GB8415092D0 (en) 1984-06-13 1984-07-18 Lepetit Spa Ester derivatives
GB8425685D0 (en) 1984-10-11 1984-11-14 Lepetit Spa Antibiotic a 40926 complex
GB8428619D0 (en) 1984-11-13 1984-12-19 Lepetit Spa Derivatives of antibiotic l 17046
US4914187A (en) 1984-11-13 1990-04-03 Gruppo Lepetit S.P.A Ester derivatives of antibiotic L 17046
GB8512795D0 (en) 1985-05-21 1985-06-26 Lepetit Spa Increasing ratio of components of teicoplanin a2 complex
GB8531846D0 (en) 1985-12-30 1986-02-05 Lepetit Spa Antibiotic a 40926 mannosyl aglycon
GB8608809D0 (en) 1986-04-11 1986-05-14 Lepetit Spa Antibiotic
GB8621911D0 (en) 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GB8621912D0 (en) 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GR871488B (en) 1986-10-10 1987-11-12 Lepetit Spa New antibiotics
GB8715735D0 (en) 1987-07-03 1987-08-12 Lepetit Spa De-mannosyl teicoplanin derivatives
US4882313A (en) 1987-07-31 1989-11-21 Smithkline Beckman Corporation Carboxamide derivatives of glycopeptides
GB8726859D0 (en) 1987-11-17 1987-12-23 Lepetit Spa 22-dechlorotei-coplanins
EP0376041B1 (en) 1988-12-27 1996-02-28 GRUPPO LEPETIT S.p.A. C63-Amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy-teicoplanins
IE64155B1 (en) 1989-03-29 1995-07-12 Lepetit Spa New substituted alkylamide derivatives of teicoplanin
JPH03193735A (en) * 1989-12-22 1991-08-23 Shionogi & Co Ltd Stabilized composition of glycopeptide-based antibiotic
US5030619A (en) 1990-04-16 1991-07-09 Miles Inc. Synergistic fungicidal composition
US5606036A (en) 1991-03-27 1997-02-25 Gruppo Lepetit Spa Antibiotic A 40926 ester derivatives
CZ285703B6 (en) 1991-07-29 1999-10-13 Biosearch Italia S. P. A. Amide derivatives of a-40926 antibiotic, process of their preparation and pharmaceutical composition containing thereof
US6384013B1 (en) 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5882900A (en) 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
CN1036654C (en) * 1993-01-01 1997-12-10 格鲁波莱佩蒂特公司 Amide derivatives of antibiotic A 40926
ES2115424T3 (en) 1995-02-07 1998-06-16 Biosearch Italia Spa BASIC PROLIN-AMIDIC DERIVATIVES OF THE ANTIBIOTICS GE 2270 AND SIMILAR TO GE 2270.
DK0808326T3 (en) 1995-02-07 2001-10-01 Biosearch Italia Spa Basic oxazolinamide derivatives of GE2270 and GE2270-like antibiotics
JP2000505438A (en) 1996-02-14 2000-05-09 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ Derivatives of antibiotic GE2270 factor C 2a, D 2 and E
AU2441697A (en) 1996-04-12 1997-11-07 Eli Lilly And Company Covalently-linked glycopeptide dimers
WO1997040067A1 (en) 1996-04-23 1997-10-30 Biosearch Italia S.P.A. Improved chemical process for preparing amide derivatives of antibiotic a 40926
US5935238A (en) 1997-06-19 1999-08-10 Sun Microsystems, Inc. Selection from multiple fetch addresses generated concurrently including predicted and actual target by control-flow instructions in current and previous instruction bundles
EP0931834A3 (en) 1997-12-23 2002-06-26 Eli Lilly And Company Echinocandin binding domain of 1,3-Beta-glucan synthase
US6417180B1 (en) * 1998-10-07 2002-07-09 University Of Massachusetts Zinc finger-reactive antimicrobial compounds
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
JP4931282B2 (en) * 2000-10-02 2012-05-16 日本ケミカルリサーチ株式会社 Bioactive peptide-containing powder
CN1330372C (en) * 2000-11-07 2007-08-08 诺华疫苗和诊断公司 Stabilized Inteferon compsns
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20050090433A1 (en) 2002-11-18 2005-04-28 Vicuron Pharmaceuticals, Inc Dalbavancin compositions for treatment of bacterial infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926

Also Published As

Publication number Publication date
RU2006136736A (en) 2008-06-10
KR20080048093A (en) 2008-05-30
HK1103639A1 (en) 2007-12-28
JP2007534768A (en) 2007-11-29
ZA200607888B (en) 2008-03-26
CA2564112A1 (en) 2006-07-27
NZ550053A (en) 2011-01-28
AU2005325261B2 (en) 2010-11-11
KR100930982B1 (en) 2009-12-10
WO2006078277A2 (en) 2006-07-27
ZA200607889B (en) 2007-12-27
US20050004051A1 (en) 2005-01-06
BRPI0510269B8 (en) 2021-05-25
RU2008142899A (en) 2010-05-10
AU2011200423B2 (en) 2012-11-29
CA2564112C (en) 2014-08-05
KR20070015179A (en) 2007-02-01
CN1964736A (en) 2007-05-16
US20050004050A1 (en) 2005-01-06
JP2013014613A (en) 2013-01-24
EP1748786A4 (en) 2009-07-15
NO20064287L (en) 2006-10-24
NO345529B1 (en) 2021-03-29
MXPA06012301A (en) 2007-03-15
IL178207A0 (en) 2007-07-04
RU2352353C2 (en) 2009-04-20
JP5207734B2 (en) 2013-06-12
SG152274A1 (en) 2009-05-29
EP1748786A2 (en) 2007-02-07
CN1964736B (en) 2012-07-04
US7119061B2 (en) 2006-10-10
AU2005325261A1 (en) 2006-07-27
AU2011200423A1 (en) 2011-02-24
BRPI0510269B1 (en) 2019-08-06
NZ588109A (en) 2012-05-25
BRPI0510269A (en) 2007-10-30
IL178207A (en) 2014-05-28

Similar Documents

Publication Publication Date Title
WO2006078277A3 (en) Dalbavancin compositions for treatment of bacterial infections
WO2006086107A3 (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs
EE200300295A (en) A quinuclidine carbamate derivative, its preparation and its use in the preparation of a medicament for the treatment of respiratory, urinary or gastrointestinal diseases, and a pharmaceutical composition containing it.
WO2005011734A3 (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
HUS1900037I1 (en) Oral antimicrobial pharmaceutical compositions
MXPA03010085A (en) Composition and methods for treatment of hyperplasia.
IL151503A0 (en) Therapeutic combinations of antihypertensive and antiagiogenic agents
WO2005096990A3 (en) Novel modification of medical prostheses
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2005102392A3 (en) Combinations for treating hiv infection
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
MXPA05005338A (en) Methods of administering dalbavancin for treatment of bacterial infections.
WO2005034883A3 (en) A method of healing skin wounds in mammals and a composition therefor
WO2004012655A3 (en) Anti-microbial compositions and methods of using same
HK1121936A1 (en) Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2006034001A3 (en) Methods of treating hiv infection
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2005074986A3 (en) Bioactive species capable of interfering with a microbial toxin-antitoxin complex and methods for evaluation and use of said bioactive species
EP2889034A3 (en) Compositions and methods of treatment comprising ceftaroline
EP1637132A4 (en) External preparation for athlete´s foot treatment
DE602004005564D1 (en) Pharmaceutical composition for thrombin peptide derivatives
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2007076053A3 (en) Stable s-nitrosothiol formulations
WO2008057196A3 (en) Methods and compositions using immunomodulatory compounds for the treatment and management of spirochete and other obligate intracellular bacterial diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006/07889

Country of ref document: ZA

Ref document number: 178207

Country of ref document: IL

Ref document number: 200607889

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 550053

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005325261

Country of ref document: AU

Ref document number: 5604/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005856652

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12006502068

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2005325261

Country of ref document: AU

Date of ref document: 20050426

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005325261

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 06106466

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2564112

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/012301

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020067022355

Country of ref document: KR

Ref document number: 2007510906

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006136736

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580018563.2

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020067022355

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005856652

Country of ref document: EP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: PI0510269

Country of ref document: BR